Previous attempts were made to develop ABCB1 inhibitors for clinical use to overcome multidrug resistance, but they failed in clinical trials primarily because the trials did not limit patient selection to those whose tumours were nonresponsive to treatment due to ABC transporter overexpression [28,35]. The gene discussed is ABCG2; the disease is neoplasm.